Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 3, 2006, Pages 1413-1423

  Waldhauser, Katri Maria ^a   Török, Michael ^a   Ha, Huy Riem ^b   Thomet, Urs ^c   Konrad, Daniel ^c   Brecht, Karin ^a   Follath, Ferenc ^b   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Bsys Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(2 BUTYLBENZOFURAN 3 YL)(4 HYDROXY 3,5 DIIODOPHENYL)METHANONE; (2 N BUTYL 3 [3,5 DIIIODO 4 DIETHYLAMINOETHOXYBENZOYL]BENZOFURAN; [(2 BUTYLBENZOFURAN 3 YL)(4 ETHOXY 3,5 DIIODOPHENYL)METHANONE; [(2 BUTYLBENZOFURAN 3 YL)[4 (2 HYDROXYETHOXY) 3,5 DIIODOPHENYL]METHANONE; [[4 (2 BUTYLBENZOFURAN 3 CARBONYL) 2,6 DIIODOPHENYL]ACETIC ACID; ALCOHOL; AMIODARONE; D DIPROPYLAMIODARONE; DIDEETHYLAMIODARONE; DRUG METABOLITE; LACTATE DEHYDROGENASE; LIPOCORTIN 5; MONO N DESETHYLAMIODARONE; N DIMETHYLAMIODARONE; PALMITIC ACID; POTASSIUM CHANNEL HERG; PROPIDIUM IODIDE; PROPIONAMIDE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; APOPTOSIS; ARTICLE; CELL POPULATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; FATTY ACID OXIDATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL; LIVER MITOCHONDRION; LIVER TOXICITY; MALE; MITOCHONDRIAL TOXICITY; NONHUMAN; OXYGEN CONSUMPTION; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; RESPIRATORY CHAIN;

ADENOSINE TRIPHOSPHATE; AMIODARONE; ANIMALS; ANNEXIN A5; ANTI-ARRHYTHMIA AGENTS; APOPTOSIS; CELL LINE; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; CHEMISTRY, PHYSICAL; CHO CELLS; COLORING AGENTS; CRICETINAE; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HEPATITIS, TOXIC; HEPATOCYTES; INDICATORS AND REAGENTS; MALE; MITOCHONDRIA, LIVER; NECROSIS; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; PROPIDIUM; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SOLUBILITY;

EID: 33751166410     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.108993     Document Type: Article

References (42)

1. Anonymous (1997) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350:1417-1424.
2. Berry MN (1974) High-yield preparation of morphologically intact isolated parenchymal cells from rat liver. Methods Enzymol 32:625-632.
3. Braumann T (1986) Determination of hydrophobic parameters by reversed-phase liquid chromatography: theory, experimental techniques, and application in studies on quantitative structure-activity relationships. J Chromatogr 373:191-225.
4. Bravo AE, Drewe J, Schlienger RG, Krahenbuhl S, Pargger H, and Ummenhofer W (2005) Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature. Crit Care Med 33:128-134.
5. Carlsson B, Singh BN, Temciuc M, Nilsson S, Li YL, Mellin C, and Malm J (2002) Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. J Med Chem 45:623-630.
6. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, and Curiel R (1994) Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 344:493-498.
7. Eguchi Y, Shimizu S, and Tsujimoto Y (1997) Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57:1835-1840.
8. Estabrook R (1967) Mitochondrial respiratory control and polarographic measurement of ADP:O ratios. Methods Enzymol 10:41-47.
9. Fabre G, Julian B, Saint-Aubert B, Joyeux H, and Berger Y (1993) Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 21:978-985.
10. Flaharty KK, Chase SL, Yaghsezian HM, and Rubin R (1989) Hepatotoxicity associated with amiodarone therapy. Pharmacotherapy 9:39-44.
11. Flanagan RJ, Storey GC, Holt DW, and Farmer PB (1982) Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J Pharm Pharmacol 34:638-643.
12. Freneaux E, Labbe G, Letteron P, The Le D, Degott C, Geneve J, Larrey D, and Pessayre D (1988) Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 8:1056-1062.
13. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, and Pessayre D (1990a) Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 255:1377-1384.
14. Fromenty B, Fisch C, Labbe G, Degott C, Deschamps D, Berson A, Letteron P, and Pessayre D (1990b) Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 255:1371-1376.
15. Fromenty B and Pessayre D (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67:101-154.
16. Gornall AG, Bardawill GJ, and David M (1949) Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751-766.
17. Ha HR, Bigler L, Wendt B, Maggiorini M, and Follath F (2005) Identification and quantitation of novel metabolites of amiodarone in plasma of treated patients. Eur J Pharm Sci 24:271-279.
18. Ha HR, Stieger B, Grassi G, Altorfer HR, and Follath F (2000) Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. Eur J Clin Pharmacol 55:807-814.
19. Harjai KJ and Licata AA (1997) Effects of amiodarone on thyroid function. Ann Intern Med 126:63-73.
20. Hohnloser SH, Klingenheben T, and Singh BN (1994) Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 121:529-535.
21. Hoppel C, DiMarco JP, and Tandler B (1979) Riboflavin and rat hepatic cell structure and function. Mitochondrial oxidative metabolism in deficiency states. J Biol Chem 254:4164-4170.
22. Huang TH, Lii CK, Chou MY, and Kao CT (2000) Lactate dehydrogenase leakage of hepatocytes with AH26 and AH Plus sealer treatments. J Endod 26:509-511.
23. Jessurun GA, Boersma WG, and Crijns HJ (1998) Amiodarone-induced pulmonary toxicity. Predisposing factors, clinical symptoms and treatment. Drug Saf 18:339-344.
24. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, and Krahenbuhl S (2005) Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41:925-935.
25. Kennedy JA, Unger SA, and Horowitz JD (1996) Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52:273-280.
26. Krahenbuhl S, Chang M, Brass EP, and Hoppel CL (1991) Decreased activities of ubiquinol:ferricytochrome c oxidoreductase (complex III) and ferrocytochrome c:oxygen oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin[c-lactam]-induced methylmalonic aciduria. J Biol Chem 266:20998-21003.
27. Lasselle PA and Sundet SA (1941) The action of sodium on 2,2′-dichlorodiethylamine. J Am Chem Soc 63:2374-2376.
28. Leist M, Single B, Castoldi AF, Kuhnle S, and Nicotera P (1997) Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 185:1481-1486.
29. Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, Rusnock EJ, Wolke A, Benjamin SB, Seeff LB, et al. (1990) Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 21:59-67.
30. Lewis JH, Ranard RC, Caruso A, Jackson LK, Mullick F, Ishak KG, Seeff LB, and Zimmerman HJ (1989) Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 9:679-685.
31. Morse RM, Valenzuela GA, Greenwald TP, Eulie PJ, Wesley RC, and McCallum RW (1988) Amiodarone-induced liver toxicity. Ann Intern Med 109:838-840.
32. Pollak PT (1999) Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. Am J Cardiol 84:37R-45R.
33. Pollak PT, Sharma AD, and Carruthers SG (1990) Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol 65:1185-1191.
34. Quaglino D, Ha HR, Duner E, Bruttomesso D, Bigler L, Follath F, Realdi G, Pettenazzo A, and Baritussio A (2004) Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. Am J Physiol 287:L438-L447.
35. Rigas B, Rosenfeld LE, Barwick KW, Enriquez R, Helzberg J, Batsford WP, Josephson ME, and Riely CA (1986) Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann Intern Med 104:348-351.
36. Singh BN (1996) Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 78:41-53.
37. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, et al. (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352:1861-1872.
38. Spaniol M, Bracher R, Ha HR, Follath F, and Krahenbuhl S (2001a) Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 35:628-636.
39. Spaniol M, Brooks H, Auer L, Zimmermann A, Solioz M, Stieger B, and Krahenbuhl S (2001b) Development and characterization of an animal model of carnitine deficiency. Eur J Biochem 268:1876-1887.
40. Vassault A (1983) Lactate dehydrogenase, in Methods of Enzymatic Analysis (Bergmeyer HU ed) pp 118-125, Wiley-VHC, Weinheim, Germany.
41. Wang H and Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 27:612-616.
42. Yang NC, Ho WM, Chen YH, and Hu ML (2002) A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP. Anal Biochem 306:323-327.